摘要
从新版药典编撰伊始到出炉,一直受到业内人士的关注。从周福成的介绍中,我们不难看出药典委员会及相关人员在鼓励创新、把关药品质量和配合国家相关政策方面所作出的不懈努力。然而,标准提高了,现实的药品研发和生产能否跟得上?
From beginning of compiling to completion,Chinese Pharmacopoeia(2010) has been attracted the attention from pharmaceutical industry.We can see the unremitting efforts of the Pharmacopoeia Commission and the relevant staff in encouraging innovation and meeting the relevant national pharmaceutical policy.However,can pharmaceutical R&D and manufacturing in reality keep up with the improved standards?
出处
《中国处方药》
2009年第11期10-11,共2页
Journal of China Prescription Drug
